Clinical Trial Update: Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Epirubicin to Docetaxel plus Cyclophosphamide in lymph node negative, ER-positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Ruijin Hospital | Conditions: Breast Neoplasms | Phase 4 | Status: COMPLETED